

ENZO BIOCHEM INC  
Form 8-K  
April 24, 2014  
UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT Pursuant**

**to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **April 22, 2014**

**Enzo Biochem, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**New York**

(State or Other Jurisdiction of Incorporation)

**001-09974**

(Commission File Number)

**13-2866202**

(IRS Employer Identification No.)

**527 Madison Avenue**

**New York, New York**

(Address of Principal Executive Offices) (Zip Code)

**10022**

**(212) 583-0100**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Edgar Filing: ENZO BIOCHEM INC - Form 8-K

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.**

Enzo Biochem, Inc. (the “Company”), along with its subsidiary Enzo Life Sciences, Inc. entered into a Settlement Agreement as of April 22, 2014 (the “Agreement”) with Affymetrix, Inc. (“Affymetrix”) with respect to actions between the Company and Affymetrix before the U.S. District Court, Southern District of New York, Cases No 03-CV-8907 and 04-CV-1555.

As a result of the Agreement, Affymetrix will pay \$5,100,000 in settlement of the aforementioned cases. Enzo’s release of Affymetrix does not include the litigation currently pending against Affymetrix in the District of Delaware and any of the claims there asserted.

The Agreement is filed with this current report as Exhibit 10.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

Exhibit No.	Description
10.1	Settlement Agreement as of April 22, 2014 among Enzo Biochem, Inc., Enzo Life Sciences, Inc. and Affymetrix, Inc.
99.1	Press Release of Enzo Biochem, Inc., dated April 24, 2014.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: April 24, 2014 By: /s/ Barry W. Weiner  
Barry W. Weiner  
President

**EXHIBIT INDEX**

10.1 Settlement Agreement as of April 22, 2014 among Enzo Biochem, Inc., Enzo Life Sciences, Inc. and Affymetrix, Inc.

99.1 Press Release of Enzo Biochem, Inc., dated April 24, 2014.